

# Clara Bueno

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7871373/publications.pdf>

Version: 2024-02-01

52  
papers

1,691  
citations

318942

23  
h-index

340414

39  
g-index

53  
all docs

53  
docs citations

53  
times ranked

3578  
citing authors

#	ARTICLE	IF	CITATIONS
1	A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL. <i>Molecular Therapy</i> , 2022, 30, 550-563.	3.7	21
2	The insecticides permethrin and chlorpyrifos show limited genotoxicity and no leukemogenic potential in human and murine hematopoietic stem progenitor cells. <i>Haematologica</i> , 2022, 107, 544-549.	1.7	3
3	The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia. <i>Cancers</i> , 2022, 14, 1593.	1.7	1
4	Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia. <i>Molecular Oncology</i> , 2022, 16, 2899-2919.	2.1	5
5	HDAC7 is a major contributor in the pathogenesis of infant t(4;11) proB acute lymphoblastic leukemia. <i>Leukemia</i> , 2021, 35, 2086-2091.	3.3	8
6	Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant MLL-rearranged B cell acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	14
7	Telomerase RNA recruits RNA polymerase II to target gene promoters to enhance myelopoiesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2015528118.	3.3	8
8	Engraftment characterization of risk-stratified AML patients in NSGS mice. <i>Blood Advances</i> , 2021, 5, 4842-4854.	2.5	5
9	<i>KMT2A-CBL</i> rearrangements in acute leukemias: clinical characteristics and genetic breakpoints. <i>Blood Advances</i> , 2021, 5, 5617-5620.	2.5	1
10	Impaired Condensin Complex and Aurora B kinase underlie mitotic and chromosomal defects in hyperdiploid B-cell ALL. <i>Blood</i> , 2020, 136, 313-327.	0.6	16
11	Pro-inflammatory cytokines favor the emergence of ETV6-RUNX1-positive pre-leukemic cells in a model of mesenchymal niche. <i>British Journal of Haematology</i> , 2020, 190, 262-273.	1.2	25
12	Shared D-J rearrangements reveal cell of origin of TCF3-ZNF384 and PTPN11 mutations in monozygotic twins with concordant BCP-ALL. <i>Blood</i> , 2020, 136, 1108-1111.	0.6	5
13	Robustness of Catalytically Dead Cas9 Activators in Human Pluripotent and Mesenchymal Stem Cells. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 20, 196-204.	2.3	12
14	Bone Marrow Clonogenic Myeloid Progenitors from NPM1-Mutated AML Patients Do Not Harbor the NPM1 Mutation: Implication for the Cell-Of-Origin of NPM1+ AML. <i>Genes</i> , 2020, 11, 73.	1.0	2
15	Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2019, 104, 778-788.	1.7	17
16	GATA2 Promotes Hematopoietic Development and Represses Cardiac Differentiation of Human Mesoderm. <i>Stem Cell Reports</i> , 2019, 13, 515-529.	2.3	27
17	Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs. <i>Blood</i> , 2019, 134, 1059-1071.	0.6	62
18	Enhanced hemato-endothelial specification during human embryonic differentiation through developmental cooperation between <i>AF4-MLL</i> and <i>MLL-AF4</i> fusions. <i>Haematologica</i> , 2019, 104, 1189-1201.	1.7	15

#	ARTICLE	IF	CITATIONS
19	Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis. <i>Haematologica</i> , 2019, 104, 1176-1188.	1.7	76
20	Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment. <i>Nucleic Acids Research</i> , 2019, 47, 5016-5037.	6.5	23
21	Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2019, 133, 2291-2304.	0.6	87
22	CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity. <i>Leukemia</i> , 2019, 33, 2090-2125.	3.3	30
23	Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 12, 134-144.	1.8	77
24	NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2019, 33, 1557-1569.	3.3	30
25	Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory in <i>in vivo</i> preclinical models of hematopoietic reconstitution and severe colitis. <i>Haematologica</i> , 2019, 104, e54-e58.	1.7	12
26	Epigenome-wide analysis reveals specific DNA hypermethylation of T cells during human hematopoietic differentiation. <i>Epigenomics</i> , 2018, 10, 903-923.	1.0	11
27	Detection of inflammatory monocytes but not mesenchymal stem/stromal cells in peripheral blood of patients with myelofibrosis. <i>British Journal of Haematology</i> , 2018, 181, 133-137.	1.2	7
28	IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML. <i>Oncotmmunology</i> , 2018, 7, e1477460.	2.1	11
29	The "Never-Ending" Mouse Models for MLL-Rearranged Acute Leukemia Are Still Teaching Us. <i>HemaSphere</i> , 2018, 2, e57.	1.2	8
30	Efficient Recreation of t(11;22) EWSR1-FLI1+ in Human Stem Cells Using CRISPR/Cas9. <i>Stem Cell Reports</i> , 2017, 8, 1408-1420.	2.3	52
31	Generation and characterization of a human iPSC cell line expressing inducible Cas9 in the "safe harbor" AAVS1 locus. <i>Stem Cell Research</i> , 2017, 21, 137-140.	0.3	26
32	Genetic Rescue of Mitochondrial and Skeletal Muscle Impairment in an Induced Pluripotent Stem Cells Model of Coenzyme Q10 Deficiency. <i>Stem Cells</i> , 2017, 35, 1687-1703.	1.4	24
33	Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes. <i>Stem Cell Reports</i> , 2017, 8, 1573-1586.	2.3	73
34	<i>RUNX1</i> Regulates Hematopoietic Differentiation of Human Pluripotent Stem Cells Possibly in Cooperation with Proinflammatory Signaling. <i>Stem Cells</i> , 2017, 35, 2253-2266.	1.4	17
35	Autogenous Control of 5' TOP mRNA Stability by 40S Ribosomes. <i>Molecular Cell</i> , 2017, 67, 55-70.e4.	4.5	78
36	Proinflammatory signals are insufficient to drive definitive hematopoietic specification of human HSCs <i>in vitro</i> . <i>Experimental Hematology</i> , 2017, 45, 85-93.e2.	0.2	11

#	ARTICLE	IF	CITATIONS
37	Human acute leukemia induced pluripotent stem cells: a unique model for investigating disease development and pathogenesis. <i>Stem Cell Investigation</i> , 2017, 4, 55-55.	1.3	3
38	The AF4-MLL fusion transiently augments multilineage hematopoietic engraftment but is not sufficient to initiate leukemia in cord blood CD34+ cells. <i>Oncotarget</i> , 2017, 8, 81936-81941.	0.8	13
39	Modeling mixed-lineage-rearranged leukemia initiation in CD34 <sup>+</sup> cells: a "CRISPR" solution. <i>Haematologica</i> , 2017, 102, 1467-1468.	1.7	1
40	Cellular Ontogeny and Hierarchy Influence the Reprogramming Efficiency of Human B Cells into Induced Pluripotent Stem Cells. <i>Stem Cells</i> , 2016, 34, 581-587.	1.4	18
41	Intra-Bone Marrow Transplantation Confers Superior Multilineage Engraftment of Murine Aorta-Gonad Mesonephros Cells Over Intravenous Transplantation. <i>Stem Cells and Development</i> , 2016, 25, 259-265.	1.1	10
42	Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency. <i>Stem Cell Reports</i> , 2016, 7, 602-618.	2.3	38
43	Human embryonic stem cell-derived mesenchymal stromal cells ameliorate collagen-induced arthritis by inducing host-derived indoleamine 2,3 dioxygenase. <i>Arthritis Research and Therapy</i> , 2016, 18, 77.	1.6	39
44	Activated <i>KRAS</i> Cooperates with MLL-AF4 to Promote Extramedullary Engraftment and Migration of Cord Blood CD34+ HSPC But Is Insufficient to Initiate Leukemia. <i>Cancer Research</i> , 2016, 76, 2478-2489.	0.4	37
45	Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia. <i>Blood</i> , 2015, 126, 2676-2685.	0.6	100
46	NF- $\kappa$ B activation impairs somatic cell reprogramming in ageing. <i>Nature Cell Biology</i> , 2015, 17, 1004-1013.	4.6	91
47	H3K4me1 marks DNA regions hypomethylated during aging in human stem and differentiated cells. <i>Genome Research</i> , 2015, 25, 27-40.	2.4	119
48	HOXA9 promotes hematopoietic commitment of human embryonic stem cells. <i>Blood</i> , 2014, 124, 3065-3075.	0.6	85
49	Bone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease. <i>Haematologica</i> , 2014, 99, 1168-1175.	1.7	36
50	Cord blood-derived CD34+ hematopoietic cells with low mitochondrial mass are enriched in hematopoietic repopulating stem cell function. <i>Haematologica</i> , 2013, 98, 1022-1029.	1.7	72
51	Enforced expression of MLL-AF4 fusion in cord blood CD34+ cells enhances the hematopoietic repopulating cell function and clonogenic potential but is not sufficient to initiate leukemia. <i>Blood</i> , 2011, 117, 4746-4758.	0.6	84
52	The ROCK Inhibitor Y-27632 Negatively Affects the Expansion/Survival of Both Fresh and Cryopreserved Cord Blood-Derived CD34+ Hematopoietic Progenitor Cells. <i>Stem Cell Reviews and Reports</i> , 2010, 6, 215-223.	5.6	43